MALVERN, PA — TELA Bio (NASDAQ: TELA) has approved inducement equity awards for five newly hired employees, signaling continued investment in talent as the medical technology company advances its commercial-stage growth strategy.
The company said its board’s Compensation Committee authorized restricted stock unit grants covering a total of 14,250 shares of common stock, with a grant date of January 20. The awards were issued under the Nasdaq Rule 5635(c)(4) inducement grant exception and were a material part of the employees’ employment compensation packages.
The restricted stock units will vest in equal annual installments over four years, contingent on each employee’s continued service with the company through the applicable vesting dates.
TELA Bio said the inducement grants are intended to attract and retain skilled professionals as it expands the commercialization of its soft-tissue reconstruction technologies.
The Malvern-based company operates as a commercial-stage medical technology firm focused on improving clinical outcomes by preserving and restoring a patient’s own anatomy. Its products are designed to support natural healing while reducing long-term exposure to permanent synthetic materials, an approach the company says offers both clinical and economic advantages for surgeons and health systems.
The equity awards reflect TELA Bio’s broader strategy of aligning employee incentives with long-term performance as it continues to scale operations in a competitive medtech market.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.